Jazz Pharmaceuticals JAZZ Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Prepaid Expense and Other Assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's increase (decrease) in prepaid expense and other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's increase (decrease) in prepaid expense and other assets?
- Jazz Pharmaceuticals (JAZZ) reported increase (decrease) in prepaid expense and other assets of -$51.9M in Q1 2026.
- How has Jazz Pharmaceuticals's increase (decrease) in prepaid expense and other assets changed year-over-year?
- Jazz Pharmaceuticals's increase (decrease) in prepaid expense and other assets decreased by 25.4% year-over-year, from -$41.4M to -$51.9M.
- What is the long-term trend for Jazz Pharmaceuticals's increase (decrease) in prepaid expense and other assets?
- Over 2 years (2021 to 2023), Jazz Pharmaceuticals's increase (decrease) in prepaid expense and other assets has grown at a 23.5% compound annual growth rate (CAGR), from $83.32M to $127.12M.